Since the introduction of insulin almost a century ago, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, and multiple sclerosis (Muttenthaler et al., 2021)
It's largely anecdotal, based on the logical (but not necessarily scientifically validated) idea that putting the peptide closer to the site of injury will make it work better or faster
The list identifies carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacteriaceae , as well as rifampicin-resistant Mycobacterium tuberculosis , as critical threats
Industry observers have described APLB as one of the fastest-scaling ingredient-focused K-beauty brands globally
Prescribers can compare options and pricing on platforms like eNavvi
BioMed Res Int 2019:8086257